The therapeutic effect of aucubin-supplemented hyaluronic acid on interleukin-1beta-stimulated human articular chondrocytes

Teng Le Huang, Shu Hua Yang, Yi Ru Chen, Jo Yu Liao, Yun Tang, Kai Chiang Yang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Injection of exogenous hyaluronic acid (HA) into the joint capsule improves symptoms of early stage osteoarthritis (OA). However, reactive oxygen species degrade HA into small oligosaccharides that can elicit pro-inflammatory responses. Likewise, disturbance of the antioxidant enzyme system and generation of oxidative stress by pro-inflammatory cytokines worsen knee OA. Accordingly, we proposed the use of aucubin, an antioxidant and anti-inflammatory compound, as a versatile adjuvant to HA for treating OA. Methods: Primary human chondrocytes were cultured in media supplemented with aucubin in a series of concentrations (0, 0.01, 0.1, 1, and 10 μg/ml) to study dose-dependent toxicity. We then evaluated the therapeutic effects of HA (100 μg/ml) supplemented with aucubin (10 μg/ml) on interleukin-1 beta (IL-1β, 10 ng/ml)-stimulated chondrocytes. Results: The use of aucubin did not change cell viability or alter lactate dehydrogenase release to normal chondrocytes. Although the proliferation and sulfated glycosaminoglycan production were not affected, aucubin partially restored the hypertrophic transformation of chondrocytes. Relative to treatment with HA or aucubin alone, real-time PCR revealed that aucubin-supplemented HA down-regulated the mRNA levels of tumor necrosis factor-alpha (TNF-α), corrected collagen type 1 and aggrecan, and up-regulated tissue inhibitor of metalloproteinase 1. Moreover, ELISA testing also showed a reduced TNF-α production. Although superoxide dismutases activity was still distributed, aucubin restored total antioxidant capacity of IL-1β-stimulated chondrocytes. Western blotting further showed that aucubin inhibited cyclooxygenase-2 and regulated the nuclear factor (erythroid-derived 2)-like 2 pathway. Conclusion: Aucubin can enhance the anti-catabolic and anti-inflammatory effects of HA on OA chondrocytes.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalPhytomedicine
Volume53
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Therapeutic Uses
Hyaluronic Acid
Chondrocytes
Interleukin-1beta
Joints
Osteoarthritis
Antioxidants
A73025
Interleukin-1
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
aucubin
Far-Western Blotting
Joint Capsule
Aggrecans
Tissue Inhibitor of Metalloproteinase-1
Knee Osteoarthritis
Cyclooxygenase 2
Collagen Type I
Oligosaccharides

Keywords

  • Aucubin
  • Hyaluronic acid
  • Osteoarthritis
  • Oxidative stress
  • Pro-inflammatory cytokine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine

Cite this

The therapeutic effect of aucubin-supplemented hyaluronic acid on interleukin-1beta-stimulated human articular chondrocytes. / Huang, Teng Le; Yang, Shu Hua; Chen, Yi Ru; Liao, Jo Yu; Tang, Yun; Yang, Kai Chiang.

In: Phytomedicine, Vol. 53, 01.02.2019, p. 1-8.

Research output: Contribution to journalArticle

Huang, Teng Le ; Yang, Shu Hua ; Chen, Yi Ru ; Liao, Jo Yu ; Tang, Yun ; Yang, Kai Chiang. / The therapeutic effect of aucubin-supplemented hyaluronic acid on interleukin-1beta-stimulated human articular chondrocytes. In: Phytomedicine. 2019 ; Vol. 53. pp. 1-8.
@article{aa1ba6da233f47a0b2ea1aa20664f30a,
title = "The therapeutic effect of aucubin-supplemented hyaluronic acid on interleukin-1beta-stimulated human articular chondrocytes",
abstract = "Background: Injection of exogenous hyaluronic acid (HA) into the joint capsule improves symptoms of early stage osteoarthritis (OA). However, reactive oxygen species degrade HA into small oligosaccharides that can elicit pro-inflammatory responses. Likewise, disturbance of the antioxidant enzyme system and generation of oxidative stress by pro-inflammatory cytokines worsen knee OA. Accordingly, we proposed the use of aucubin, an antioxidant and anti-inflammatory compound, as a versatile adjuvant to HA for treating OA. Methods: Primary human chondrocytes were cultured in media supplemented with aucubin in a series of concentrations (0, 0.01, 0.1, 1, and 10 μg/ml) to study dose-dependent toxicity. We then evaluated the therapeutic effects of HA (100 μg/ml) supplemented with aucubin (10 μg/ml) on interleukin-1 beta (IL-1β, 10 ng/ml)-stimulated chondrocytes. Results: The use of aucubin did not change cell viability or alter lactate dehydrogenase release to normal chondrocytes. Although the proliferation and sulfated glycosaminoglycan production were not affected, aucubin partially restored the hypertrophic transformation of chondrocytes. Relative to treatment with HA or aucubin alone, real-time PCR revealed that aucubin-supplemented HA down-regulated the mRNA levels of tumor necrosis factor-alpha (TNF-α), corrected collagen type 1 and aggrecan, and up-regulated tissue inhibitor of metalloproteinase 1. Moreover, ELISA testing also showed a reduced TNF-α production. Although superoxide dismutases activity was still distributed, aucubin restored total antioxidant capacity of IL-1β-stimulated chondrocytes. Western blotting further showed that aucubin inhibited cyclooxygenase-2 and regulated the nuclear factor (erythroid-derived 2)-like 2 pathway. Conclusion: Aucubin can enhance the anti-catabolic and anti-inflammatory effects of HA on OA chondrocytes.",
keywords = "Aucubin, Hyaluronic acid, Osteoarthritis, Oxidative stress, Pro-inflammatory cytokine",
author = "Huang, {Teng Le} and Yang, {Shu Hua} and Chen, {Yi Ru} and Liao, {Jo Yu} and Yun Tang and Yang, {Kai Chiang}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.phymed.2018.09.233",
language = "English",
volume = "53",
pages = "1--8",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",

}

TY - JOUR

T1 - The therapeutic effect of aucubin-supplemented hyaluronic acid on interleukin-1beta-stimulated human articular chondrocytes

AU - Huang, Teng Le

AU - Yang, Shu Hua

AU - Chen, Yi Ru

AU - Liao, Jo Yu

AU - Tang, Yun

AU - Yang, Kai Chiang

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Injection of exogenous hyaluronic acid (HA) into the joint capsule improves symptoms of early stage osteoarthritis (OA). However, reactive oxygen species degrade HA into small oligosaccharides that can elicit pro-inflammatory responses. Likewise, disturbance of the antioxidant enzyme system and generation of oxidative stress by pro-inflammatory cytokines worsen knee OA. Accordingly, we proposed the use of aucubin, an antioxidant and anti-inflammatory compound, as a versatile adjuvant to HA for treating OA. Methods: Primary human chondrocytes were cultured in media supplemented with aucubin in a series of concentrations (0, 0.01, 0.1, 1, and 10 μg/ml) to study dose-dependent toxicity. We then evaluated the therapeutic effects of HA (100 μg/ml) supplemented with aucubin (10 μg/ml) on interleukin-1 beta (IL-1β, 10 ng/ml)-stimulated chondrocytes. Results: The use of aucubin did not change cell viability or alter lactate dehydrogenase release to normal chondrocytes. Although the proliferation and sulfated glycosaminoglycan production were not affected, aucubin partially restored the hypertrophic transformation of chondrocytes. Relative to treatment with HA or aucubin alone, real-time PCR revealed that aucubin-supplemented HA down-regulated the mRNA levels of tumor necrosis factor-alpha (TNF-α), corrected collagen type 1 and aggrecan, and up-regulated tissue inhibitor of metalloproteinase 1. Moreover, ELISA testing also showed a reduced TNF-α production. Although superoxide dismutases activity was still distributed, aucubin restored total antioxidant capacity of IL-1β-stimulated chondrocytes. Western blotting further showed that aucubin inhibited cyclooxygenase-2 and regulated the nuclear factor (erythroid-derived 2)-like 2 pathway. Conclusion: Aucubin can enhance the anti-catabolic and anti-inflammatory effects of HA on OA chondrocytes.

AB - Background: Injection of exogenous hyaluronic acid (HA) into the joint capsule improves symptoms of early stage osteoarthritis (OA). However, reactive oxygen species degrade HA into small oligosaccharides that can elicit pro-inflammatory responses. Likewise, disturbance of the antioxidant enzyme system and generation of oxidative stress by pro-inflammatory cytokines worsen knee OA. Accordingly, we proposed the use of aucubin, an antioxidant and anti-inflammatory compound, as a versatile adjuvant to HA for treating OA. Methods: Primary human chondrocytes were cultured in media supplemented with aucubin in a series of concentrations (0, 0.01, 0.1, 1, and 10 μg/ml) to study dose-dependent toxicity. We then evaluated the therapeutic effects of HA (100 μg/ml) supplemented with aucubin (10 μg/ml) on interleukin-1 beta (IL-1β, 10 ng/ml)-stimulated chondrocytes. Results: The use of aucubin did not change cell viability or alter lactate dehydrogenase release to normal chondrocytes. Although the proliferation and sulfated glycosaminoglycan production were not affected, aucubin partially restored the hypertrophic transformation of chondrocytes. Relative to treatment with HA or aucubin alone, real-time PCR revealed that aucubin-supplemented HA down-regulated the mRNA levels of tumor necrosis factor-alpha (TNF-α), corrected collagen type 1 and aggrecan, and up-regulated tissue inhibitor of metalloproteinase 1. Moreover, ELISA testing also showed a reduced TNF-α production. Although superoxide dismutases activity was still distributed, aucubin restored total antioxidant capacity of IL-1β-stimulated chondrocytes. Western blotting further showed that aucubin inhibited cyclooxygenase-2 and regulated the nuclear factor (erythroid-derived 2)-like 2 pathway. Conclusion: Aucubin can enhance the anti-catabolic and anti-inflammatory effects of HA on OA chondrocytes.

KW - Aucubin

KW - Hyaluronic acid

KW - Osteoarthritis

KW - Oxidative stress

KW - Pro-inflammatory cytokine

UR - http://www.scopus.com/inward/record.url?scp=85055646980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055646980&partnerID=8YFLogxK

U2 - 10.1016/j.phymed.2018.09.233

DO - 10.1016/j.phymed.2018.09.233

M3 - Article

AN - SCOPUS:85055646980

VL - 53

SP - 1

EP - 8

JO - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

ER -